Answers are grounded in this paper and cite their sources.
Review highlights effectiveness and safety of Lu PSMA-617 in metastatic prostate cancer, suggesting its potential role in therapy.
A BSTRACT Due to the prevalence of prostate cancer among men worldwide, cutting-edge, efficient treatment options must be developed. The lutetium prostate-specific membrane antigen 617 (Lu PSMA-617), a newly approved medicine for the treatment of prostate cancer, is reviewed in this article. The prostate-specific membrane antigen (PSMA), a cell surface protein seen in prostate cancer cells, targets the radioligand therapy called Lu PSMA-617. The delivery of beta-emitting lutetium 177 to PSMA-showing cancer cells results in localized radiation that causes cell death, which is the mechanism of action of Lu PSMA-617, examined in this article. The review includes the clinical trials to assess Lu PSMA-617’s effectiveness and safety in patients with metastatic castration-resistant prostate cancer. With notable increases in the survival rate and prostate-specific antigen response rates, these trials have produced encouraging findings. Lu PSMA-617 is a possible therapy for refractory cases because it has demonstrated efficacy even in individuals who have failed numerous lines of treatment. This article also covers the negative consequences of Lu PSMA-617, such as hematological toxicity, xerostomia, and renal toxicity. Continuing clinical trials examining Lu PSMA-617 in various therapeutic contexts, including early stages of prostate cancer and combination therapy, are shown as a conclusion to this review.
No takes yet. Share an insight, caveat, or question.
Agrawal et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: